

**DONCASTER and BASSETLAW AREA PRESCRIBING COMMITTEE
MINUTES from Thursday 22nd February 2018**

Present:

<u>NHS Doncaster CCG</u>		<u>RDaSH FT</u>		<u>Doncaster LPC</u>	
Dr David Crichton – (APC Chair)	✓	Mr Stephen Davies – Chief Pharmacist RDaSH FT	✓	Mr Richard Harris – LPC Representative	✓
		Mr Andrew Houston - Senior Mental Health Pharmacist		Mr M Ahmed - Deputy	
Mrs Gill Bradley – Deputy Head of Medicines Management (NHSD-MMT)				<u>DBTHFT</u>	
Dr Rachel Sykes – NHS Doncaster GP	✓	Mrs Heidi Atkinson- Non Medical Prescriber Representative (RDaSH DCIS)		Mr Andrew Barker – Chief Pharmacist DBTHFT	
<u>NHS Bassetlaw CCG</u>		Ms Julie Hall - Non Medical Prescriber Representative (RDaSH DCIS)		Mr Lee Wilson – Consultant Pharmacist DBTHFT	
Mr Rob Wise – Head of Medicines Management (BCCG)		<u>Doncaster LMC</u>		Dr Lucy Peart – Acute Physician DBTHFT	✓
		Dr Dean Eggitt - LMC Secretary		Mr John Bane – Deputy Chief Pharmacist DBTHFT	✓
		Mr David Gibbons - LMC Deputy		<u>FCMS (When necessary)</u>	
		Dr Rमित Shah – LMC Chair	✓	Mrs Nicola Sanders Mrs Alison O’Conner Mrs Annie Armitage Mr Andrew Shakesby	✓

Minutes Only: Dr Mark Pickering Doncaster Offender Health, Chair prisons D&T Committee

Dr Rupert Suckling & Mr Victor Joseph DMBC

In Attendance: Angie Machin – Minute Secretary (NHS Doncaster-MMT)

Agenda Item	Discussion Points	Action By
01/18/1	<p>Apologies Apologies were received from Mrs G Bradley, Mr R Wise, Mrs A Armitage</p> <p>Dr L Peart was welcomed to the meeting followed by introduction to the Committee members.</p>	
01/18/2	<p>Declarations of Interest, Gifts or Hospitality Mr R Harris advised the Committee that he was working with Glaxo Smith Kline to deliver a meeting on inhaler technique. The chair made a decision that this would not impact upon decisions to be made today and Mr Harris could participate fully in discussions.</p>	

02/18/3	<p>Minutes of last meeting</p> <p>The minutes of the last meeting held on the 25th January 2018 were agreed as a true and accurate record and will be made available on the medicines management website.</p>	
02/18/4.1	<p>Matters Arising</p> <p>As confirmation, the Committee was advised that the Transgender paperwork has been added to the medicines management website.</p>	
11/15/8.4	<p>Shared Cared Protocol/Pathway update for the management of ADHD in adults, young people and Children</p> <p>To be discussed at the March meeting.</p>	
10/16/8.2	<p>Parkinson's disease – Shared Care Protocol review</p> <p>A proposal has been made by Sheffield CCG to take forward a joint South Yorkshire and Bassetlaw document. The Committee agreed to this suggestion. This will be fed back to Sheffield CCG.</p>	NHSD-MMT(GB)
10/17/8.1	<p>FreeStyle Libre Glucose Monitoring System</p> <ul style="list-style-type: none"> • RDaSHFT update <p>There are ongoing discussions with RDaSHFT and DBTHFT Paediatrics around a business plan.</p> <ul style="list-style-type: none"> • Sheffield APG Position Statement <p>The Committee discussed the statement produced by Sheffield APG. This statement does not reflect the RMOG statement for prescribing. The Committee agreed that Doncaster and Bassetlaw will maintain the current GREY TLS status and that feedback via the Heads of Medicines Management (HoMM) meeting should include:</p> <ul style="list-style-type: none"> • The word 'fear' in the following sentence could be too subjective: <i>CGM/Freestyle Libre may be used where fear of hypoglycaemia provokes clinically significant anxiety and is a barrier to good control.</i> • There is a lack of consistency in the handover to Primary Care; the adult pathway (12 months) appears to be more comprehensive than the children's pathway (1 month). • There could be potential issues where patients are seen in Sheffield although are living in Doncaster or Bassetlaw (Grey on the TLS). <p>The Committee does acknowledge that moving forward there will be a need for a joint agreement and suggested that this acknowledgement should be shared at the next HoMM meeting.</p>	NHSD-MMT(GB)
11/17/19.2	<p>Methotrexate injections –change from Red to Amber on TLS</p> <p>The pathway and supply route meeting with DBTHFT and the LPC to discuss this follows today's APC meeting. Feedback from this will be shared at the meeting in March.</p>	NHSD-MMT(GB)

01/18/8.2	<p>Melatonin for REM Sleep Disorder – in Parkinson’s Disease The Committee was advised that the opinion of Sheffield CCG had been sought regarding their current categorisation of melatonin for this indication. Note, unlicensed indications are still black. The Committee agreed that at this time it would not be appropriate to support prescribing for this indication.</p>	NHSB- MMT
02/18/5	<p>Traffic Light – Drugs for Review There are no drugs for review this month</p>	
02/18/6	<p>APC Officers actions There are no officer’s actions this month</p>	
02/18/7	<p>Traffic Light – Additions for Consideration There are no drugs for consideration this month</p>	
02/18/8	<p>New Business</p>	
02/18/8.1	<p>Sheffield SCP for Epilepsy in Paediatrics The Committee was asked for comments on the content of the SCP paperwork. The document is in draft and feedback is welcomed. The Committee suggested clarity around the wording in the dosage section for specific drugs including:</p> <ul style="list-style-type: none"> • Brivaracetam Licenced for use over 16 years Adjunctive therapy of partial-onset seizures with or without secondary generalisation <i>At a Consultant’s discretion, Brivaracetam can be prescribed for children younger than 16 years of age.</i> • Clobazam Licensed for use in child 6 months to 3 years in exceptional circumstances (not licensed for children under 3 years) Adjunctive therapy or monotherapy under specialist supervision for catamearia seizures. <p>The Committee agreed that Primary Care will need support around the titration/stability of medication and this should be included in any commissioning arrangements made. RDaSHFT confirmed that there is a Paediatric Epilepsy Specialist Nurse that supports titration for children in Doncaster. NHSD-MMT will feed these comments back to Sheffield via the HoMM meeting.</p>	NHSD- MMT(GB)
02/18/8.2	<p>Use of Avastin (off-label) for Age Related Macular Degeneration Communication from NHS Clinical Commissioners (NHSCC) has been distributed informing that they along with The Royal College of Ophthalmologists (RCOphth) and NICE (NG82) support the use of Avastin (off label) for the treat of wet age related macular degeneration (AMD). This has also been acknowledged as</p>	

	<p>reasonable by the General Medical Council. Keith Ridge the Chief Pharmaceutical Officer for England has released a statement highlighting that the guidance does not cover health professionals other than medics (i.e. Pharmacists). DBTHFT highlighted that:</p> <ul style="list-style-type: none"> • MHRA could raise some concerns • The volume of the drug required is different from its licensed indications and therefore a third party would be required to prepare it into smaller doses. • The administration process is unclear <p>Locally the South Yorkshire and Bassetlaw ACS Medicines Management Steering Group plan to seek opinion from ophthalmologists to aid further discussion. The Committee acknowledged that there is pressure on CCG's from the recent published NHS planning guidance to use Avastin for this indication. At this stage there are no actions taken from this Committee.</p>	
02/18/8.3	<p>Gluten Free national consultation The national consultation has now been published and the option agreed was option 3:</p> <ul style="list-style-type: none"> • To only allow the prescribing of certain GF foods <p>The Committee was asked to consider if all items other than bread and bread mix should be added to the TLS as Grey. This was agreed and the local guidance will be updated to reflect this.</p>	NHSD- MMT
02/18/8.4	<p>Sheffield SCP for Growth Hormone replacement in growth hormone deficient adults The Committee has been asked by Sheffield CCG to consider supporting the development of a joint South Yorkshire & Bassetlaw SCP. Sheffield CCG is looking to update their existing paperwork including considering the use of a switch to biosimilar somatropin to Omnitrope. The Committee does support this and suggested that the SCP was developed for all ages rather than adults only. This will be fed back to Sheffield. Any further information will be brought back to this Committee.</p>	NHSD- MMT(GB)
02/18/9	<p>DBTHFT D&TC Update No minutes available</p>	
02/18/10	<p>Formulary Liaison Group Update No minutes available</p>	
02/18/11	<p>Doncaster Prisons Drug & Therapeutic Committee No minutes available</p>	
02/18/12	<p>RDASH FT & Medicines Management Committee Update No minutes available</p>	
02/18/13	<p>Barnsley Area Prescribing Committee Update The minutes of the meeting held in January 2018 were received by the Committee</p>	
02/18/14	<p>Rotherham Area Prescribing Committee Update No minutes available</p>	
02/18/15	<p>Sheffield Area Prescribing Committee Update The minutes of the meeting held in November 2017 were received by the Committee</p>	

	It was noted that Liraglutide (Saxenda) has been categorised as black in Sheffield. This drug will be added for review in next month's horizon scanning.	
02/18/16	Nottinghamshire Area Prescribing Committee Update The minutes of the meeting held in November 2017 were received by the Committee	
02/18/17	SY& B Accountable Care System Medicines Optimisation Work-stream Steering Group The minutes of the meeting held in October and December 2017 were received by the Committee	
02/18/18	Northern Regional Medicines Optimisation Committee No minutes available	
02/18/19	Any Other Business 02/18/19.1 RDaSHFT brought the recent media attention around the benefits of anti-depressant use to the Committee. RDaSHFT confirmed that they will be discussing this at the next Formulary Liaison Group meeting. 02/18/19.2 The LMC questioned the recent NHSE transgender guidance, this was fully discussed at last month's meeting and now available on the medicines management website to support those prescribers who chose to prescribe for these patients, it was clarified that the document is not mandatory in Doncaster and Bassetlaw.	
02/18/20	Date, time & venue of next meeting 12 noon prompt Thursday 29th March 2018 in Meeting Room 3 Sovereign House	
	12 noon prompt Thursday 29th March 2018 in Meeting Room 3 Sovereign House 12 noon prompt Thursday 26th April 2018 in Meeting Room 3 Sovereign House 12 noon prompt Thursday 31st May 2018 in Meeting Room 3 Sovereign House 12 noon prompt Thursday 28th June 2018 in Meeting Room 3 Sovereign House 12 noon prompt Thursday 26th July 2018 in Meeting Room 3 Sovereign House 12 noon prompt Thursday 30th August 2018 in Meeting Room 3 Sovereign House 12 noon prompt Thursday 27th September 2018 in Meeting Room 3 Sovereign House 12 noon prompt Thursday 25th October 2018 in Meeting Room 3 Sovereign House	